/PRNewswire/ -- DeFloria, a joint venture between Ajna BioSciences and Charlotte's Web (TSX: CWEB, OTCQX: CWBHF), reported positive results from a Phase 1...

PR Newswire

United States

DeFloria Announces Positive Results from Phase 1 Trial of AJA001 Being Developed for the Treatment of Autism Spectrum Disorder (ASD)

Bacteria in the stomach and intestines affect brain development, while children with ADHD and autism generally have fewer good gut bacteria. But why? And can they be helped by improved bacterial flora?

Bakterier i mage och tarm påverkar hjärnans utveckling, samtidigt har barn med adhd och autism generellt färre goda tarmbakterier. Men varför? Och kan de bli hjälpta av förbättrad bakterieflora?

Kopplingen autism och tarm inte längre ”galen”

Media Bias/Fact Check

Svenska Dagbladet

Schibsted

Stockholm

Stockholm County

Sweden

The link autism and gut no longer "crazy"

Cision

Green Stock News for the New Green Economy.

Green Stock News

Charlotte's Web Holdings Provides Update on DeFloria's Phase 1 Results Targeting Autism Spectrum Disorder

DeFloria announced Thursday that its experimental cannabis-based drug for autism spectrum disorder showed positive early results, with patients tolerating the treatment well across multiple dose levels. The drug, AJA001, being developed as a multi-compound hemp extract with a full spectrum of cannabinoids, demonstrated safety at daily doses up to 660 mg... Please login to read all 402 words.

Green Market Report

DeFloria advances cannabis-based autism drug through early trial

Promising Findings Presented at the American College of Neuropsychopharmacology Annual Meeting LOUISVILLE, Colo., Dec. 12, 2024  /PRNewswire/ – (TSX: CWEB) (OTCQX: CWBHF) Charlotte’s Web Holdings, Inc. (“Charlotte’s Web” or the “Company”) the market leader in cannabidiol (CBD) hemp extract wellness products, is pleased to share an update on the progress of DeFloria LLC’s (“DeFloria”) botanical pharmaceutical development, an entity established by…

pressreach.com

Charlotte's Web Provides Update on DeFloria's Phase 1 Results Targeting Autism Spectrum Disorder - PressReach

newsbudz.com

DeFloria’s advances cannabis-based autism drug through early trial

Satellos Bioscience has dosed the first subject with DMD in a Phase Ib trial of its oral small molecule drug candidate, SAT-3247.The post Satellos doses first DMD subject in Phase Ib trial appeared first on Clinical Trials Arena.

Clinical Trials Arena

Satellos doses first DMD subject in Phase Ib trial

DeFloria, a joint venture between Charlotte’s Web (TSX:CWEB), Ajna BioSciences and British American Tobacco, yielded positive results from a phase-1 dose trial of AJA001, its cannabis-based drug candidate to treat symptoms of autism spectrum disorder
Results show that AJA001 was well-tolerated with a favorable pharmacokinetic profile
Charlotte’s Web specializes in wellness products made from hemp extracts including CBD and CBN
Charlotte’s Web st…

DeFloria Announces Positive Results from Phase 1 Trial of AJA001 Being Developed for the Treatment of Autism Spectrum Disorder (ASD)

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics